AACC Releases Updated Guidance to Improve Use of POC Tests for Fertility and Reproductive Health
By LabMedica International staff writers Posted on 05 Sep 2022 |
Point-of-care tests are clinical tests that are performed near the patient instead of in a central lab. Due to their convenience and rapid turnaround times, these tests can help patients to get treatment much faster than traditional tests. As a result, the use of point-of-care testing has risen steadily in all areas of healthcare. In the fertility and reproductive health fields in particular, it is now used for everything from predicting ovulation and diagnosing pregnancy to managing premature rupture of membranes (PROM) - also known as a patient's water breaking - and high-risk deliveries. However, when point-of-care tests are used inappropriately or performed incorrectly, this can lead to unnecessary follow-up tests and procedures and can even put the patient's health at risk or lead to death.
Now, the American Association for Clinical Chemistry (Washington, DC, USA) has issued a new guidance document with expert recommendations for performing point-of-care tests for fertility and reproductive health. As the use of point-of-care testing rises in these fields, this guidance is intended to ensure that patients and their babies fully benefit from it. AACC has updated guidance that it originally published in 2007 to inform healthcare professionals of the most current best practices for point-of-care testing in reproductive medicine. The highlights of the key recommendations from this document are:
- Testing for PROM using commercial kits alone is not recommended without clinical signs that a patient's water has broken. Additionally, results from these tests must be interpreted in the context of a patient's clinical presentation to prevent patient harm.
- Urine luteinizing hormone tests are accurate and reliable predictors of ovulation. These tests can improve the likelihood of conception among healthy fertile women and can also be used to time certain assisted reproduction procedures. However, further study is still needed to determine the efficacy of at-home ovulation prediction kits that use saliva or measure basal body temperature.
- While blood laboratory pregnancy tests are the gold standard, healthcare providers should consider using pregnancy point-of-care tests in situations where rapid diagnosis of pregnancy is needed for treatment decisions. One such scenario is if a patient presents to the emergency department with unstable vital signs and symptoms indicative of a ruptured ectopic pregnancy that might require surgery.
"Point-of-care testing is growing in popularity as a means of delivering faster turnaround time of test results closer to the patient," said the guidance document authors Drs. James H. Nichols, Mahesheema Ali, John I. Anetor, Li-Sheng Chen, Yu Chen, Sean Collins, Saswati Das, Sridevi Devaraj, Lei Fu, Brad S. Karon, Heba Kary, Robert D. Nerenz, Alex J. Rai, Zahra Shajani-Yi, Vinita Thakur, Sihe Wang, Hoi-Ying Elsie Yu, and Lindsey E. Zamora. "Guidance is needed for optimizing the implementation of [point-of-care testing] in patient care. This guidance document revises previous recommendations and offers best practices for the use of [point-of-care testing] in fertility and reproductive health."
Related Links:
AACC
Latest Industry News
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus
- AMP Publishes Best Practice Guidance for Slice Testing Approach in Diagnostics